Drug-drug interaction of ciprofol injectable emulsion with mefenamic acid capsules in healthy subjects

Article Pharmacology & Pharmacy

Pharmacodynamics and Pharmacokinetics of HSK3486, a Novel 2,6-Disubstituted Phenol Derivative as a General Anesthetic

Juan Liao et al.

Summary: The novel sedative/hypnotic agent HSK3486, a 2,6-disubstituted alkylphenol analogue, was characterized in this study. HSK3486 exhibited positive allosteric regulation and direct agonism of the GABA(A) receptor, with promising sedative/hypnotic effects and good in vivo pharmacokinetic properties.

FRONTIERS IN PHARMACOLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Comparison of ciprofol (HSK3486) versus propofol for the induction of deep sedation during gastroscopy and colonoscopy procedures: A multi-centre, non-inferiority, randomized, controlled phase 3 clinical trial

Junxiang Li et al.

Summary: This study compared the sedation properties of Ciprofol and propofol in patients undergoing gastroscopy and colonoscopy. The results showed that Ciprofol was non-inferior to propofol in terms of successful sedation, and had a lower occurrence rate of adverse drug reactions.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Mass balance, pharmacokinetics and pharmacodynamics of intravenous HSK3486, a novel anaesthetic, administered to healthy subjects

Yicong Bian et al.

Summary: This study investigated the pharmacokinetics of the novel anesthetic HSK3486 in healthy subjects, demonstrating its rapid onset of action and favorable safety profile.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Safety, Pharmacokinetics, and Pharmacodynamics of a Single Bolus of the γ-aminobutyric Acid (GABA) Receptor Potentiator HSK3486 in Healthy Chinese Elderly and Non-elderly

Xiaojiao Li et al.

Summary: The study found that the rate of drug-related adverse reactions was slightly higher in the elderly group compared to the non-elderly group, especially in the elderly group receiving 0.4 mg/kg dose. The recovery time was similar between the elderly receiving 0.3 mg/kg and non-elderly receiving 0.4 mg/kg.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Physiologically-Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co-Administration with the UGT Inhibitor Mefenamic Acid

Ernesto Callegari et al.

Summary: This study evaluated the drug-drug interaction of the sodium-glucose cotransporter 2 inhibitor ertugliflozin with the UGT inhibitor mefenamic acid using PBPK modeling. The results showed that mefenamic acid can impact the pharmacokinetic profile of ertugliflozin.

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)

添加到收藏夹

Article Chemistry, Medicinal